Paradoxical anti-TNF-associated TB worsening: Frequency and factors associated with IRIS

Joint Bone Spine

Volumn 83, Issue 2, 2016, Pages 173-178

  Rivoisy, Claire ^a   Tubach, Florence ^b,c   Roy, Carine ^b,c   Nicolas, Nathalie ^c   Mariette, Xavier ^b   Salmon, Dominique ^d   Lortholary, Olivier ^e   Bourgarit, Anne ^f,g   Bagheri, H ^g   Blandin, B ^g   Breban, M ^g   Bretagne, S ^g   Castot, A ^g   Chichmanian, R M ^g   Chosidow, O ^g   Dautzenberg, B ^g   Dellamonica, P ^g   Dufeu Demazes, N ^g   Emilie, D ^g   Gillet, C ^g   Hugot, J P ^g   Kreft Jais, C ^g   Lemann, M ^g   Leport, C ^g   Michelet, C ^g   Montastruc, J L ^g   Prieur, A M ^g   Ravaud, P ^g   Roux, C ^g   Vittecoq, D ^g   more..

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e IMAGINE INSTITUTE   (France)

^f HÔPITAL JEAN VERDIER   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

IRIS; TNF blockers; Tuberculosis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTI TUMOR NECROSIS FACTOR ASSOCIATED TUBERCULOSIS; ARTICLE; BEHCET DISEASE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONSENSUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE INTENSIFICATION; EXPOSURE; FEMALE; GIANT CELL ARTERITIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATORY DISEASE; MALE; MYCOBACTERIUM TUBERCULOSIS; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; TUBERCULOSIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; ARTHRITIS; CASE CONTROL STUDY; CHEMICALLY INDUCED; DISEASE COURSE; LATENT TUBERCULOSIS; MIDDLE AGED; REGISTER; RETROSPECTIVE STUDY; SKIN DISEASES, VASCULAR;

ADULT; AGED; ARTHRITIS; BIOLOGICAL THERAPY; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE AGENTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN DISEASES, VASCULAR; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959509035     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.04.022     Document Type: Article

References (18)

1. Dhasmana D.J., Dheda K., Ravn P., et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008, 68:191-208.
2. Sun H.-Y., Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis 2009, 22:394-402.
3. Karampetsou M.P., Liossis S-NC, Sfikakis P.P. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010, 103:917-928.
4. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
5. Rivoisy C., Amrouche L., Carcelain G., et al. Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: Beware of immune reconstitution inflammatory syndrome. Joint Bone Spine 2011, 78:312-315.
6. Jorge-Ripper C., Pelazas R., González-Pérez J.M., et al. [Immune reconstitution syndrome in a case of disseminated tuberculosis after withdrawal of treatment with adalimumab]. Rev Clin Esp 2012, 212:219-221.
7. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
8. Meintjes G., Lawn S.D., Scano F., et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
9. WHO Global tuberculosis report 2014 2014, World health organisation, http://www.who.int/tb/publications/global_report/en/, 168 pages.
10. Cheng V.C.C., Yam W.C., Woo P.C.Y., et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003, 22:597-602.
11. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005, 34:S12-S18.
12. Meintjes G., Wilkinson R.J., Morroni C., et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010, 24:2381-2390.
13. Legrand F., Lecuit M., Dupont B., et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008, 46:696-702.
14. Vayssade M., Tournadre A., D'Incan M., et al. Immune reconstitution inflammatory syndrome during treatment of Whipple's disease. Joint Bone Spine 2015, 82:122-124.
15. Blackmore T.K., Manning L., Taylor W.J., et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008, 47:e83-e85.
16. Wallis R.S., van Vuuren C., Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009, 48:1429-1432.
17. Brunel A.S., Reynes J., Tuaillon E., et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS 2012, 23:2110-2112.
18. Le Blay P., Rakotoniraini H., Lagier J.C., et al. A severe Whipple disease with an immune reconstitution inflammatory syndrome: an additionnal case of thalidomide efficiency. Joint Bone Spine 2014, 81:260-262.